Many countries have already realized the value of the biotech industry and are now aggressively trying to attract foreign companies in this space. But South Korea needs to up the pace to improve regulations and the innovation environment to become a more attractive market, executives at AstraZeneca say.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?